14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception

Family planning and contraceptive counseling are fundamental dimensions of comprehensive well-woman care. Grounded in autonomy, bodily integrity, and shared clinical decision-making, the certified nurse-midwife partners with patients to align individual reproductive life goals with medical safety, lifestyle preferences, and efficacy profiles. Understanding the physiological mechanisms, adverse effect profiles, anticipatory guidance, and medical safety frameworks defined by the Centers for Disease Control and Prevention (CDC) Medical Eligibility Criteria for Contraceptive Use (US MEC) and Selected Practice Recommendations (US SPR) is vital for safe clinical practice and AMCB certification.

The Contraceptive Efficacy Spectrum & Tier Architecture

Contraceptive methods are categorized into three distinct tiers based on typical-use and perfect-use annual failure rates (percentage of individuals experiencing an unintended pregnancy during the first year of use). Contraceptive efficacy is fundamentally governed by the degree to which the method depends on continuous, correct user compliance.

Contraceptive Efficacy Hierarchy (Typical-Use Failure Rates)
├── Tier 1: Long-Acting Reversible Contraception (LARC) & Permanent (<1%)
│   ├── Subdermal Etonogestrel Implant (Nexplanon) ──> 0.05%
│   ├── Levonorgestrel Intrauterine Devices (LNG-IUD) ──> 0.1% - 0.2%
│   ├── Copper Intrauterine Device (ParaGard) ──> 0.6% - 0.8%
│   ├── Vasectomy ──> 0.15% (Requires 3-month post-procedure semen confirmation)
│   └── Bilateral Tubal Ligation / Salpingectomy ──> 0.5%
├── Tier 2: Hormonal & User-Adherence Dependent Methods (4% - 7%)
│   ├── Depot Medroxyprogesterone Acetate (DMPA Injection) ──> 4%
│   ├── Combined Oral Contraceptive Pills (COCs) ──> 7%
│   ├── Progestin-Only Pills (POPs) ──> 7%
│   ├── Transdermal Contraceptive Patch ──> 7%
│   └── Contraceptive Vaginal Rings ──> 7%
└── Tier 3: Coitus-Dependent & Barrier Methods (13% - 28%)
    ├── Male Latex / Polyurethane Condoms ──> 13% (Only method offering STI protection)
    ├── Diaphragm with Spermicide ──> 17%
    ├── Fertility Awareness-Based Methods (FABMs) ──> 15% - 24%
    ├── Coitus Interruptus (Withdrawal) ──> 20%
    ├── Internal (Female) Condoms ──> 21%
    ├── Contraceptive Sponge ──> 14% (nulliparous) / 27% (parous)
    └── Spermicides Alone (Nonoxynol-9) ──> 28%

The CDC Medical Eligibility Criteria (US MEC) System

The CDC US MEC provides evidence-based guidance on the safety of contraceptive methods in the presence of specific medical conditions:

• Category 1: A condition for which there is no restriction for the use of the contraceptive method.
• Category 2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks (safe to use; routine clinical follow-up).
• Category 3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method (use is not recommended unless other more appropriate methods are unavailable or unacceptable; requires expert clinical consultation).
• Category 4: A condition that represents an unacceptable health risk if the contraceptive method is used (strictly contraindicated; absolute medical prohibition).

Long-Acting Reversible Contraception (LARC)

Long-acting reversible contraceptives (LARCs) include the subdermal etonogestrel implant and intrauterine devices (IUDs). Because they require no user intervention following placement, their typical-use failure rates are identical to their perfect-use failure rates (<1% annually), representing the most effective reversible methods available.

1. Etonogestrel Subdermal Implant (Nexplanon)

• Device Characteristics: A single 4 cm × 2 mm ethylene vinyl acetate rod preloaded in a sterile disposable applicator, containing 68 mg of etonogestrel (a potent third-generation progestin).
• Mechanism of Action: Releases ~60 to 70 mcg/day initially, slowly declining to ~25 to 30 mcg/day by year 3. The primary mechanism is sustained suppression of ovulation by suppressing the mid-cycle luteinizing hormone (LH) surge via negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis. Secondary mechanisms include thickening of cervical mucus (creating a barrier to sperm penetration within 24 hours of placement) and endometrial thinning/atrophy.
• Efficacy & Duration: Typical failure rate is 0.05% (higher efficacy than surgical sterilization). FDA approved for 3 years, but extensive multicenter clinical trials and ACOG/CDC practice bulletins support high efficacy through 5 years of continuous use.
• Anticipatory Bleeding Guidance & Management:
  • Unscheduled, irregular bleeding is the most common side effect and the leading cause of premature discontinuation (~15%). Bleeding changes do not reflect decreased efficacy or structural pathology.
  • Patterns include: amenorrhea (~20%), infrequent bleeding (~30%), frequent bleeding (~10%), or prolonged spotting (~15%–20%). The bleeding pattern experienced in the first 3 months typically predicts future bleeding patterns.
  • First-Line Medical Therapy for Troublesome Bleeding: A 5- to 7-day course of scheduled nonsteroidal anti-inflammatory drugs (Ibuprofen 800 mg PO TID with meals or Mefenamic acid 500 mg PO TID) to suppress endometrial prostaglandin synthesis and microvascular breakdown. Alternatively, a 10- to 20-day course of low-dose combined oral contraceptives (or oral estradiol 1 to 2 mg daily) can stabilize the fragile endometrial vascular bed.
• Insertion Anatomy: Inserted subdermally in the inner aspect of the non-dominant upper arm, 8 to 10 cm proximal to the medial epicondyle of the humerus, overlying the groove between the biceps and triceps muscles, avoiding the sulcus to prevent injury to the ulnar nerve and brachial vessels.

2. Levonorgestrel Intrauterine Devices (LNG-IUDs)

• Formulations:
  • Mirena: 52 mg LNG (initial release 20 mcg/day); FDA approved for 8 years; approved for contraception and heavy menstrual bleeding.
  • Liletta: 52 mg LNG (initial release 20 mcg/day); FDA approved for 8 years.
  • Kyleena: 19.5 mg LNG (initial release 17.5 mcg/day); FDA approved for 5 years; smaller frame and narrower inserter barrel.
  • Skyla: 13.5 mg LNG (initial release 14 mcg/day); FDA approved for 3 years.
• Mechanism of Action: High local intrauterine concentration of levonorgestrel induces profound endometrial decidualization and glandular atrophy, rendering the endometrium unreceptive to blastocyst implantation. It thickens cervical mucus to impede sperm ascension and impairs uterotubal sperm motility. Importantly, most cycles remain ovulatory (especially after the first year), preserving endogenous ovarian estradiol production.
• Clinical Benefits: Produces a 70% to 90% reduction in menstrual blood loss; first-line therapy for idiopathic heavy menstrual bleeding and adenomyosis; significant alleviation of dysmenorrhea and endometriosis pain. Amenorrhea rates reach 20% to 50% by 12 months with 52 mg devices.
• Insertion Protocol & Sounding: Perform bimanual examination to establish uterine position and axis. Apply antiseptic solution to cervix. Place a single-tooth tenaculum on the anterior lip (or posterior lip if retroverted) and exert gentle axial counter-traction to straighten the cervico-uterine angle. Sound the uterine cavity with a sterile sound: normal depth is 6 to 10 cm (do NOT insert if sounded depth is <6 cm). Advance the loaded inserter to fundal depth, deploy the arms, release the device, and trim strings to 3 to 4 cm from the external os.
• Complications & Infection Timing: Uterine perforation occurs in approximately 1 per 1,000 insertions (higher in lactating women due to myometrial softness). Expulsion occurs in 2% to 10% (highest in the first year and following immediate post-abortion or postpartum placement). The risk of pelvic inflammatory disease (PID) is elevated ONLY during the first 20 days following insertion, resulting from the introduction of cervical microflora into the uterine cavity during insertion; after 20 days, the background PID risk returns to that of the general population.

3. Copper Intrauterine Device (ParaGard T 380A)

• Device Characteristics: Polyethylene T-frame wound with 380 mm² of pure copper wire and copper sleeves; completely non-hormonal.
• Mechanism of Action: Continuous dissolution of copper ions into the endometrial cavity incites a sterile local inflammatory reaction characterized by foreign-body leukocytic, macrophage, and cytokine infiltration. Copper ions are directly cytotoxic and spermicidal, profoundly inhibiting sperm motility, viability, capacitation, and the acrosome reaction, preventing fertilization.
• Efficacy & Duration: Failure rate is 0.6% to 0.8%. FDA approved for 10 years, with extensive clinical trial data demonstrating high efficacy through 12 years.
• Clinical Profile & Side Effects: Excellent choice for individuals seeking non-hormonal contraception or those with absolute contraindications to estrogens and progestins (e.g., active breast cancer). Expected adverse effects include an increase in menstrual blood loss (30% to 50%) and dysmenorrhea, most prominent in the first 3 to 6 months. Prophylactic scheduled NSAIDs during menses provide effective symptom relief.